GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

OPK · Jun 30, 2026

OPKO HEALTH, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001193125-26-318090General Corporate
Debt relative to revenue50thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.debt_to_revenue

213.38% · OPTIONAL · VALID

Capex intensity10thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.84% · OPTIONAL · VALID

Operating cash generation22thOwn-history percentile · N=9
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-26.59% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

4.32% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure60thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

37.81% · OPTIONAL · VALID

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

48.92% · CORE · NOT_ENOUGH_HISTORY

Operating margin80thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-4.26% · CORE · VALID

R&D intensity70thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

20.28% · OPTIONAL · VALID

SBC intensity10thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1.34% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building
Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20250/9 normalizedLevel 3Dec 31, 20256/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
278.33%
Current
213.38%
Delta
-64.95%
Capex Intensity Increased
Previous
1.48%
Current
1.84%
Delta
0.36%
Cash Generation Decreased
Previous
-15.55%
Current
-26.59%
Delta
-11.04%
Growth Increased
Previous
-17.18%
Current
4.32%
Delta
21.50%
Inventory Pressure Decreased
Previous
51.85%
Current
37.81%
Delta
-14.04%
Margin Increased
Previous
36.84%
Current
48.92%
Delta
12.08%
Profitability Increased
Previous
-41.08%
Current
-4.26%
Delta
36.82%
R And D Intensity Decreased
Previous
23.51%
Current
20.28%
Delta
-3.24%
Sbc Intensity Decreased
Previous
2.20%
Current
1.34%
Delta
-0.86%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · OPKO HEALTH, INC. →Transitioned To · OPK Fundamental State →Transitioned To · OPK BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · OPK CAPEX_INTENSITY_INCREASED →Transitioned To · OPK CASH_GENERATION_DECREASED →Transitioned To · OPK GROWTH_INCREASED →Transitioned To · OPK INVENTORY_PRESSURE_DECREASED →Transitioned To · OPK MARGIN_INCREASED →Transitioned To · OPK PROFITABILITY_INCREASED →Transitioned To · OPK R_AND_D_INTENSITY_DECREASED →Transitioned To · OPK SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.